Llwytho...
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Clin Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Clinical Oncology
2011
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/ https://ncbi.nlm.nih.gov/pubmed/21788559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|